Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASPH | Q12797 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29882303 | 1.00 | ASPH (0.59) | ASPHKDM4EKDM8HTTHSD17B10 | |
| SCHEMBL28310940 | 0.88 | KDM4E (0.47) | ASPHKDM4EKDM8HTTHSD17B10 | |
| SCHEMBL28311764 | 0.87 | HTT (0.45) | ASPHKDM4EKDM8HTTHSD17B10 | |
| SCHEMBL18988808 | 0.86 | KDM4E (0.56) | ASPHKDM4EKDM8HTTHSD17B10 | |
| SCHEMBL25342306 | 0.84 | KDM4E (0.58) | ASPHKDM4EKDM8NAPRTKDM4A | |
| SCHEMBL1720768 | 0.84 | L3MBTL1 (0.46) | ASPHKDM4EKDM8HTTHSD17B10 | |
| SCHEMBL17509160 | 0.84 | P2RX7 (0.42) | ASPHKDM4EKDM8HTTHSD17B10 | |
| SCHEMBL9928615 | 0.84 | SLC6A9 (0.42) | ASPHKDM4EKDM8HTTHSD17B10 | |
| SCHEMBL2582882 | 0.80 | KDM4E (0.44) | ASPHKDM4EKDM8HTTHSD17B10 | |
| SCHEMBL29760859 | 0.80 | KDM4E (0.44) | ASPHKDM4EKDM8HTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110950797-A | Preparation method of 2-trifluoromethyl-3-fluoro-4-picolinic acid and derivatives thereof | 丽水绿氟科技有限公司 | 2020-04-03 | — | — | CN | claimed |
| CN-110627714-A | Synthetic method of 3-fluoro-2-trifluoromethyl isonicotinic acid | 安庆博曼生物技术有限公司 | 2019-12-31 | — | — | CN | claimed |
| EP-4682149-A1 | POLYMORPH OF JAK TYROSINE KINASE INHIBITOR AND USE THEREOF | Prime Gene Therapeutics Co., Ltd. (CN) | 2026-01-21 | — | — | EP | disclosed |
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-11-13 | — | — | US | disclosed |
| WO-2025233901-A1 | ACTIVATORS OF PYRUVATE KINASE ISOFORM M2 AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025054488-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2025-01-30 | — | — | US | disclosed |
| WO-2024193495-A1 | FUMARATE CRYSTAL FORM OF JAK TYROSINE KINASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 北京普祺医药科技股份有限公司 | 2024-09-26 | — | — | WO | disclosed |
| WO-2024193496-A1 | METHOD FOR PREPARING PYRROLOPYRIMIDINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 北京普祺医药科技股份有限公司 | 2024-09-26 | — | — | WO | disclosed |
| EP-4415706-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | Vanqua Bio, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| US-12065441-B2 | Pyrazolopyrimidine derivative, use thereof and pharmaceutical composition | Gengle Therapeutics, Inc. (CN) | 2024-08-20 | — | — | US | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2012093101-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2012-07-12 | — | — | WO | disclosed |
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-06-14 | — | — | US | disclosed |
| WO-2012068450-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2012-05-24 | — | — | WO | disclosed |
| EP-2406265-A2 | SUBSTITUTED 3-AMINOISOXAZOLOPYRIDINES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-01-18 | — | — | EP | disclosed |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| WO-2011112662-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2010102778-A2 | SUBSTITUTED 3-AMINOISOXAZOLOPYRIDINES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2010-09-16 | — | — | WO | disclosed |
| US-20100234419-A1 | SUBSTITUTED 3-AMINOISOXAZOLOPYRIDINES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | ASPH 2393/4885KDM4E 3762/4885KDM8 3760/4885 |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | ASPH 2393/4885KDM4E 4092/4885KDM8 4026/4885 |
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | ASPH 2421/4885KDM4E 818/4885KDM8 541/4885 |
| US-20100234419-A1 | SUBSTITUTED 3-AMINOISOXAZOLOPYRIDINES AS KCNQ2/3 MODULATORS | KCNQ1, KCNQ2, KCNQ3 | ASPH 4000/4885KDM4E 328/4885KDM8 1561/4885 |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | ASPH 3087/4885KDM4E 248/4885KDM8 972/4885 |
| US-12065441-B2 | Pyrazolopyrimidine derivative, use thereof and pharmaceutical composition | JAK2, JAK1, JAK3 | ASPH 3832/4885KDM4E 2256/4885KDM8 1668/4885 |
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | WRN, RECQL, BLM | ASPH 3464/4885KDM4E 3487/4885KDM8 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.